Stewart D J, Futter N, Irvine A, Danjoux C, Moors D
Ontario Cancer Treatment and Research Foundation, Ottawa Regional Cancer Centre, Canada.
Am J Clin Oncol. 1987 Dec;10(6):520-2. doi: 10.1097/00000421-198712000-00013.
Fifteen patients with advanced renal-cell carcinoma were treated with the combination of mitomycin-C 14-20 mg/m2 i.v. every 7 weeks and metronidazole 1,500 mg/m2 p.o. 12 and 1 h before and 6 and 24 h after the mitomycin-C. Of 12 patients evaluable for response, three (25%) responded with partial remissions. Myelosuppression did not appear to be increased over that seen with mitomycin-C alone. Pulmonary toxicity occurred in three patients and was fatal in two. The incidence of pulmonary toxicity was probably increased over that seen with mitomycin-C alone. Renal toxicity was also seen. Based on this small study, it was our feeling that this dose-schedule of metronidazole did not appear to result in enough of an augmentation of the efficacy of mitomycin-C against renal-cell carcinoma to justify the incidence of serious toxicity.
15例晚期肾细胞癌患者接受了丝裂霉素-C（14 - 20mg/m²静脉注射，每7周一次）与甲硝唑（1500mg/m²口服，在丝裂霉素-C给药前12小时和1小时以及给药后6小时和24小时服用）联合治疗。在12例可评估疗效的患者中，3例（25%）出现部分缓解。与单独使用丝裂霉素-C相比，骨髓抑制似乎并未加重。3例患者出现肺部毒性，其中2例死亡。肺部毒性的发生率可能比单独使用丝裂霉素-C时有所增加。也观察到了肾毒性。基于这项小型研究，我们认为这种甲硝唑剂量方案似乎并未充分增强丝裂霉素-C对肾细胞癌的疗效，无法证明其严重毒性的发生率是合理的。
